QNTM Stock Overview
A biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Quantum BioPharma Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$7.15 |
| 52 Week High | CA$130.00 |
| 52 Week Low | CA$4.85 |
| Beta | 0.76 |
| 11 Month Change | -6.90% |
| 3 Month Change | 25.44% |
| 1 Year Change | -94.42% |
| 33 Year Change | -93.60% |
| 5 Year Change | -98.27% |
| Change since IPO | -99.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| QNTM | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -0.7% | -5.2% | 1.3% |
| 1Y | -94.4% | -23.4% | 23.1% |
Return vs Industry: QNTM underperformed the Canadian Pharmaceuticals industry which returned -22.3% over the past year.
Return vs Market: QNTM underperformed the Canadian Market which returned 21.7% over the past year.
Price Volatility
| QNTM volatility | |
|---|---|
| QNTM Average Weekly Movement | 17.2% |
| Pharmaceuticals Industry Average Movement | 12.0% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.8% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: QNTM's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: QNTM's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 17 | Zeeshan Saeed | www.fsdpharma.com |
Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
Quantum BioPharma Ltd. Fundamentals Summary
| QNTM fundamental statistics | |
|---|---|
| Market cap | CA$13.53m |
| Earnings (TTM) | -CA$14.30m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.0x
P/E RatioIs QNTM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QNTM income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$10.24m |
| Earnings | -US$10.24m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.33 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 2.0% |
How did QNTM perform over the long term?
See historical performance and comparison